1-phenyl-5-(trifluoromethyl)pyridin-2(1H)-one | 914918-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-phenyl-5-(trifluoromethyl)pyridin-2(1H)-one
• 英文别名: 2(1H)-Pyridinone,1-phenyl-5-(trifluoromethyl)-；1-phenyl-5-(trifluoromethyl)pyridin-2-one
• CAS: 914918-70-0
• 化学式: C₁₂H₈F₃NO
• 分子量: 239.197
• InChiKey: IGQFRTANNWAYRG-UHFFFAOYSA-N

物化性质

• 沸点：
  281.5±40.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-iodo-1-phenylpyridin-2(1H)-one 、 (三氟甲基)三甲基硅烷 在 potassium fluoride 、 copper(l) iodide 作用下， 以 六甲基磷酰三胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以78%的产率得到1-phenyl-5-(trifluoromethyl)pyridin-2(1H)-one
  参考文献：
  名称：

  The modified trifluoromethylation protocol applicable to electronically deficient iodopyridinones

  摘要：

  Utilization of a mixed solvent system of DMF/HMPA=1/1 (v/v) to the KF/Cul/TMSCF3 reagent system proved to significantly affect the reaction, realizing convenient introduction of a trifluoromethyl (CF3) group not only to electron-deficient iodopyridinones with quite a few previous successful examples but also to aliphatic vinylic iodides. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.07.029

文献信息

• PREPARATION OF 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS
  申请人：Hu Gaoyun

  公开号：US20120129859A1

  公开（公告）日：2012-05-24

  1-(substituted benzyl)-5-trifluoromethyl-2(1H)pyridone compounds and their pharmaceutical acceptable salts are disclosed. The preparation methods of the compounds and their salts and the use of the same for preparing the medicaments for treating fibrosis are also disclosed. New pyridine compounds and their salts are obtained from trifluoromethyl pyridone as starting material.

  揭示了1-(取代苄基)-5-三氟甲基-2(1H)吡啶酮化合物及其药用可接受盐。还公开了这些化合物及其盐的制备方法，以及用于制备治疗纤维化药物的用途。从三氟甲基吡啶酮作为起始物获得了新的吡啶化合物及其盐。
• <i>N</i>- and <i>O</i>-arylation of pyridin-2-ones with diaryliodonium salts: base-dependent orthogonal selectivity under metal-free conditions
  作者：Masami Kuriyama、Natsumi Hanazawa、Yusuke Abe、Kotone Katagiri、Shimpei Ono、Kosuke Yamamoto、Osamu Onomura

  DOI：10.1039/d0sc02516j

  日期：——

  N- and O-arylation reactions of pyridin-2-ones as ambident nucleophiles have been achieved with diaryliodonium salts on the basis of base-dependent chemoselectivity. In the presence of N,N-diethylaniline in fluorobenzene, pyridin-2-ones were very selectively converted to N-arylated products in high yields. On the other hand, the O-arylation reactions smoothly proceeded with the use of quinoline in chlorobenzene

  基于对碱的化学选择性，用二芳基碘鎓盐实现了作为环境亲核体的吡啶-2-酮的无金属N-和O-芳基化反应。在氟苯中存在N，N-二乙基苯胺时，吡啶-2-酮非常有选择地以高收率转化为N-芳基化产物。另一方面，通过在氯苯中使用喹啉使O-芳基化反应顺利进行，从而导致高收率和选择性。在这些方法中，除吡啶-4-酮和一组二芳基碘鎓盐之外，还接受了多种吡啶-2-酮和一组二芳基碘鎓盐作为合适的反应伙伴。
• Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds
  申请人：Olgin Jeff

  公开号：US20100029578A1

  公开（公告）日：2010-02-04

  The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).

  本发明涉及通常用于治疗或预防房颤(AF)的化合物和方法。
• METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS
  申请人：Olgin Jeff

  公开号：US20120046321A1

  公开（公告）日：2012-02-23

  The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).

  本发明涉及一般与化合物和方法有关，用于治疗或预防心房颤动（AF）。
• METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
  申请人：Blatt Lawrence M.

  公开号：US20120258924A1

  公开（公告）日：2012-10-11

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  本发明涉及使用活性化合物调节应激激活蛋白激酶（SAPK）系统的方法，其中该活性化合物对至少一种p38 MAPK抑制的效力较低；并且该接触是在该化合物对至少一种p38 MAPK的抑制浓度低百分比的SAPK调节浓度下进行的。本发明还涉及吡非尼酮的衍生物，这些衍生物可以调节应激激活蛋白激酶（SAPK）系统。